Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.75.

A number of research firms have recently issued reports on PYXS. Weiss Ratings reissued a “sell (e+)” rating on shares of Pyxis Oncology in a report on Friday, September 25th. Wedbush increased their price target on Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Wells Fargo & Company lifted their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Finally, HC Wainwright lifted their price objective on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, September 10th.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.69 on Thursday. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The stock has a market cap of $140.96 million, a P/E ratio of -1.20 and a beta of 1.37. The firm has a fifty day moving average price of $2.63 and a 200 day moving average price of $2.16.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Sell-side analysts expect that Pyxis Oncology will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. T3 Companies LLC acquired a new stake in shares of Pyxis Oncology in the 3rd quarter valued at approximately $61,000. Commonwealth Equity Services LLC lifted its stake in Pyxis Oncology by 14.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock valued at $114,000 after buying an additional 6,295 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Pyxis Oncology by 22.0% in the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares in the last quarter. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.